AngioDynamics Inc (ANGO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $499.19M
Last updated: Nov 17, 2026 at 11:05 AM ET
AngioDynamics Inc (ANGO) Stock Forecast
Analysts expect AngioDynamics (ANGO) to earn -$0.28 per share in the fiscal year ending May 31, 2027, on revenue of $337.70M. Over the last 30 days, 0 estimates for the fiscal year ending May 31, 2027 were revised up and 2 down. For the fiscal year ending May 31, 2028, the EPS consensus is -$0.11.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 5.1%.
- Fiscal year ending May 31, 2027
- -$0.28
- EPS consensus, revenue $337.70M
- Fiscal year ending May 31, 2028
- -$0.11
- EPS consensus, revenue $354.91M
- Next report
- Jan 4, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| May 31, 2027 | -$0.28 | -$0.29 to -$0.27 | 3 | $337.70M | $337.00M to $338.42M | 4 |
| May 31, 2028 | -$0.11 | -$0.15 to -$0.06 | 3 | $354.91M | $352.00M to $360.12M | 4 |
Quarterly Estimates
Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Feb 28, 2027, at -$0.09, and highest for the quarter ending May 31, 2027, at -$0.06.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Nov 30, 2026 | -$0.07 | -$0.11 to -$0.02 | 3 | $84.27M | $83.00M to $85.40M | 4 |
| Feb 28, 2027 | -$0.09 | -$0.10 to -$0.07 | 3 | $83.25M | $81.90M to $84.00M | 4 |
| May 31, 2027 | -$0.06 | -$0.10 to -$0.02 | 5 | $91.02M | $86.24M to $95.03M | 6 |
Estimate Revisions
Across the 4 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending May 31, 2027 | 0 | 2 |
| Fiscal year ending May 31, 2028 | 1 | 0 |
| Quarter ending Nov 30, 2026 | 1 | 1 |
| Quarter ending Feb 28, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending May 31, 2027 has worsened from -$0.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending May 31, 2027 | -$0.28 | -$0.27 | -$0.27 | -$0.27 | -$0.27 | N/A |
| Fiscal year ending May 31, 2028 | -$0.11 | -$0.05 | -$0.05 | -$0.05 | -$0.05 | N/A |
| Quarter ending Nov 30, 2026 | -$0.07 | -$0.08 | -$0.08 | -$0.08 | -$0.06 | N/A |
| Quarter ending Feb 28, 2027 | -$0.09 | -$0.06 | -$0.06 | -$0.06 | -$0.06 | N/A |
Frequently Asked Questions About ANGO
What is the ANGO stock forecast?
Consensus analyst estimates put AngioDynamics's EPS at -$0.28 for the fiscal year ending May 31, 2027, on revenue of $337.70M.
What EPS do analysts expect from ANGO next year?
For the fiscal year ending May 31, 2027, the consensus EPS estimate is -$0.28, with estimates from -$0.29 to -$0.27 from 3 analysts. For the fiscal year ending May 31, 2028, the consensus EPS estimate is -$0.11, with estimates from -$0.15 to -$0.06 from 3 analysts.
What revenue do analysts expect from AngioDynamics next year?
For the fiscal year ending May 31, 2027, the consensus revenue estimate is $337.70M, with estimates from $337.00M to $338.42M. For the fiscal year ending May 31, 2028, the consensus revenue estimate is $354.91M, with estimates from $352.00M to $360.12M.
How many analysts cover ANGO?
3 analysts estimate EPS for AngioDynamics for the fiscal year ending May 31, 2027.
ANGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts